To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Agreement for Large-Scale Genotyping Studies
Illumina, Inc. has announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK).
Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium™ assays to conduct genetic studies for thousands of samples provided by GSK.
The blanket agreement enables multiple projects to be conducted over period of time.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies.
